New York City-based Mount Sinai has implemented an FDA-approved AI tool designed to improve detection of congenital heart defects in fetal ultrasounds.
The Carnegie Imaging for Women, a Mount Sinai-affiliated OB-GYN imaging facility, became the first center in New York City to adopt the AI software from BrightHeart. Researchers at Mount Sinai West used the tool to assess 200 de-identified ultrasound scans from 11 medical centers across two countries, according to a Dec. 2 news release from the health system.
Use of the AI tool led to improved detection of major congenital heart defects in more than 97% of cases, with an 18% reduction in scan reading time and a 19% increase in confidence scores. Seven OB-GYNs and seven maternal-fetal medicine specialists participated in the study, evaluating the scans both with and without AI assistance.
The software is designed to identify second-trimester ultrasound findings suspicious for severe congenital heart defects, which affect about 1 in 500 newborns and often require urgent medical or surgical intervention, the release said.
